Atomo offers highly accurate diagnostic test solutions for screening for COVID-19 at the point of care. Results are obtained in as little as 10 minutes, without the need for laboratory-based testing.
Antigen and antibody rapid testing now available in Australia.
Performing antigen and antibody tests in parallel enables detection of current or prior infection from the SARS-CoV-2 virus, thereby optimising population screening and patient triage programs.
The unique, all-in-one point of care test for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 virus in whole blood, serum, or plasma samples.
Unlike standard, multi-component rapid test kits, the AtomoRapid™ COVID-19 (IgG/IgM) Rapid Antibody Test is a single-use, handheld, integrated device that is simple to use, safe, and convenient, giving an accurate result in just 15 minutes.
The AtomoRapid™ COVID-19 (IgG/IgM) Rapid Antibody Test incorporates Atomo’s award-winning ‘Galileo’ integrated diagnostic test platform – designed and developed in Australia – for peerless safety and utility.
The Galileo platform simplifies the test procedure by removing the need for multiple test components, eliminating common user errors and improving test performance:
Developed in partnership with French biotechnology specialist NG Biotech, the AtomoRapid™ COVID-19 (IgG/IgM) Rapid Antibody Test has demonstration excellent performance in multiple independent clinical evaluations internationally*
* Van der Werf S et al (2020). Performance evaluation report for the detection of anti SARS-CoV-2 antibodies. National Reference Centre for Respiratory Infection Viruses (including influenza), Institut Pasteur, Paris.
The fast, accurate point of care test for the qualitative detection of nucleocapsid protein antigens specific to the SARS-CoV-2 virus.
Utilising nasopharyngeal or nasal swab specimens obtained from individuals suspected of having COVID-19, the Atomo COVID-19 Antigen Test is safe and easy to use, giving an accurate result in just 10 minutes.
Entered on the Australian Register of Therapeutic Goods, the AtomoRapid™ COVID-19 (IgG/IgM) Antibody Test (ARTG 341411) and the Atomo COVID-19 Antigen Test (ARTG 346587) are available now for use by registered medical practitioners; healthcare professionals in residential and aged care facilities; accredited pathology laboratories; Commonwealth, State, or Territory departments of health, and agencies acting on their behalf.